insights_auto
Perspektīva: 35.3% garā pozīcija·8.8% īsā pozīcija
Pāriet uz analīzichevron_right
NVO:NYSE
Novo Nordisk A/S
38,54 $
arrow_upward
+0,94%(+0,36) 1 d.
9. okt., 12:36:58 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
38,11 $
Augsta
38,64 $
Zema
38,06 $
Tirgus kapitalizācija
128,11 mljrd.
Vid. apjoms
13,33 milj.
Apjoms
4,24 milj.
Dividende
4,66%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,81
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,93 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
38,11 $
Augsta
38,64 $
Zema
38,06 $
Tirgus kapitalizācija
128,11 mljrd.
Vid. apjoms
13,33 milj.
Apjoms
4,24 milj.
Dividende
4,66%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,81
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,93 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Insider Monkey
·
pirms 3 stundām
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
Traders Union
·
pirms 8 stundām
Novo Nordisk stock support test at $37.43: Technical outlook
MedWatch
·
pirms 10 stundām
Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program
Investing.com
·
pirms 10 stundām
Novo Nordisk stock target cut at Citi on lack of margin growth
Profils
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com